Canurta Pitch Day, Empowering ALS Research and Reflecting on June's Accomplishments

Canurta Pitch Day Highlights

Highly anticipated Canurta Pitch Day brought together leading experts from prominent organizations in Canada and independent investors who eagerly embraced the opportunity to explore the future of Canurta's robust product line.

One of the most significant aspects was the invaluable interactions between industry pioneers and seasoned investors. These discussions went beyond surface-level inquiries, delving deep into market dynamics, scalability, and potential impact. These engaging exchanges fostered an environment of collaboration and growth, creating the foundation for long-lasting partnerships.

Eric Soubeyrand presents at Natural Health Product Research Society

Congratulations to Eric Soubeyrand, our esteemed Research Associate, for his outstanding presentation at the Natural Health Product Research Society conference in Montreal. He explored the anti-inflammatory properties of prenylated flavonoids, sparking great interest in Canadian biotech's focus on polyphenols. Eric's thoughtful responses showcased our dedication to botanical research.

ALS Canada pull to end ALS

Join Canurta, a trailblazer in harnessing the therapeutic potential of hemp polyphenols, as we proudly participate in the 2023 ALS Canada Pull to End ALS. Our mission goes beyond just pulling a 42,000-lb truck – we carry the weight of hope for a future free of ALS.

Together, let's pull together to end ALS. Make a donation and become an integral part of Canurta's mission against ALS.

Canurta's June Milestones:

Research and Development

• ARDS in vivo trial for anti-inflammatory activity of cannflavins in an acute respiratory distress model to begin at the end of month.

• Cannflavins showed inhibition of the West Nile Virus viral protease in the in vitro testing.

Business Development

• Ontario Centre of Innovation funding received to help execute our pre-clinical investigation of Cannabis-Derived Flavonoids Targeting Breast Cancer Metastasis with the University of Guelph.

Milestones for Bioinformatics

• Proof of Concept Pipeline Completed: we’ve achieved a significant milestone by finalizing our proof of concept (POC) pipeline infrastructure. This automation streamlines compound generation and screening. Ongoing optimization and testing will take place this month.

• Docking Analysis Underway: Our team has initiated the setup of a framework to analyze the interaction between our generated molecules and the ALS-related proteins. This analysis aims to deepen our understanding of the effects and potential impact of these molecules on ALS.

• Creating a Novel Molecule Database: We are currently in the process of constructing an internal database to house our innovative molecules. This valuable resource will serve as a vital tool for our ongoing research and molecular advancements.

Technology

• Accomplished demonstration of Blockchain for Supply Chain Platform during Canurta Day.

• Readying platform for deployment and in-house testing.